Barclays’s NeuroMetrix, Inc. Common Stock NURO Stock Holding History

Barclays’s Portfolio NURO Stock Details NURO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2	Closed	-$1K	–	7043
2016 Q4	$1K	Buy	+2	New	+$1.49K	﹤0.01%	6511
2014 Q1	–	Hold	0	–	–	–	7749
2013 Q4	–	Hold	0	–	–	–	7725

Other funds holding NURO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays's NURO Position: Q1 2017 in Review

Barclays sold out of NeuroMetrix, Inc. Common Stock (NURO) in Q1 2017, closing a stake of 2 shares — an estimated $1K sold.

Barclays first reported a position in NURO in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 9 funds tracked by Wall St. Rank hold NURO as of Q1 2017.

Barclays reported no remaining NeuroMetrix, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Barclays sold 2 NeuroMetrix, Inc. Common Stock shares in Q1 2017, an estimated $1K.
Barclays first reported a position in NeuroMetrix, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
Barclays's NeuroMetrix, Inc. Common Stock position peaked at $1K in Q4 2016.
9 funds tracked by Wall St. Rank held NeuroMetrix, Inc. Common Stock as of Q1 2017.

Based on Barclays's 13F filing for Q1 2017, filed 15 May 2017.